Retatrutide weight loss timeline: what the trials show

Key takeaways

• The weight came off on a slope, not a cliff. In the Phase 2 trial, the top dose (12 mg) averaged about 17.5 percent loss at 24 weeks and about 24.2 percent at 48 weeks .
• It was still falling at the finish. The 48-week average was bigger than the 24-week average in every dose group, so the curve had not leveled off when the Phase 2 trial ended .
• The first months are the dose-climb. The higher-dose arms started at 2 mg or 4 mg weekly and stepped up toward target over the early weeks , which is also when the gut side effects clustered .
• A 2026 Phase 3 readout (TRIUMPH-1, 2,339 people) extended the arc: the 12 mg dose averaged about 28 percent at 80 weeks and about 30 percent at 104 weeks in a pre-specified extension .
• This is a timeline from trials, not a personal forecast. Retatrutide is still investigational and not FDA approved, in the maker's words legally available only to people in its clinical trials, and your own pace would vary .

The timeline, stage by stage

Here is the arc from the trials, read loosely. These are averages for the highest (12 mg) dose, on a drug you cannot yet be prescribed, so treat the dates as the shape of the curve, not a calendar for you.

The early weeks are mostly the dose-climb

Nobody in the trial jumped straight to a big dose. The higher-dose groups started at a low weekly dose, 2 mg or 4 mg, and stepped up toward their target over the early weeks . That slow ramp is not red tape. It is how these drugs are made tolerable, because the gut side effects showed up mostly during that escalation period, per Lilly's published summary of the trial .

So the early scale movement tends to be real but modest, and it is happening at the same time as the queasy weeks. If you have seen people online say the first month was the hardest and the slowest, that lines up with how the trial was built: the dose, the side effects, and the patience all stack into the same window.

From the 24-week midpoint to the 48-week mark

By 24 weeks, the top dose was averaging about 17.5 percent off, versus about 1.6 percent on placebo . That is roughly the point where the dose has reached target and the body has settled into it. It is also when the trial's dose-dependent heart-rate bump peaked, before declining again over the back half .

Then the second half kept going. At 48 weeks the top-dose average was about 24.2 percent . The plain way to read that: the line from week 24 to week 48 still pointed down, in every dose group, not just the top one. The trial ended before the curve flattened, which is part of why the Phase 3 program ran longer.

The long arc: what Phase 3 added past one year

Phase 2 stopped at 48 weeks. The Phase 3 program (TRIUMPH-1, 2,339 people over 80 weeks) ran longer, and a 2026 topline from the maker reported about 28 percent average loss at 80 weeks on the 12 mg dose among people who stayed on it, and about 30 percent at 104 weeks in a pre-specified extension . That is a company release rather than a full peer-reviewed paper, so read it as a strong preview, not the last word .

The takeaway from the long arc is not a bigger headline number. It is that the loss kept accumulating well past the one-year mark before settling, which fits the gradual slope the whole timeline shows. Fast is not the story here. Steady is.

Why your own timeline would not match the chart

A trial line is an average of hundreds of people. Behind the smooth curve are fast responders, slow responders, and people who stalled or stopped. The dates above are the midpoint of all of them, not a promise for any one person.

The pace also depends on the dose you reach and whether you can stay on it. The biggest losses came on the 12 mg dose, which was also the hardest to tolerate, and the dose ladder in the trial is what the studies used, not a schedule to copy on your own.

The honest bottom line

If you want a one-line version of the timeline: the dose climbs for the first few months, the scale moves the whole way through, the Phase 2 average was still dropping at the 48-week finish, and Phase 3 kept it going past the one-year mark. Gradual, not instant.

That is the trial pattern. Whether it would be your pattern is a different question, and the honest answer is that no chart can tell you, on a drug that is still working its way through Phase 3.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 5 entries, primary canon (the NEJM Phase 2 trial and ClinicalTrials.gov) plus reputable secondary sources with inline acknowledgment (an independent CME summary of the trial design and Lilly's industry-funded Phase 2 and Phase 3 releases), last reviewed 2026-06-06.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.